Short Interest in NeuroMetrix, Inc. (NASDAQ:NURO) Declines By 36.0%

Posted by Donna Armstrong on Mar 29th, 2025

NeuroMetrix, Inc. (NASDAQ:NURO – Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 1,600 shares, a drop of 36.0% from the February 28th total of 2,500 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 18,000 shares, the short-interest ratio is presently 0.1 days.

NeuroMetrix Stock Performance

Shares of NASDAQ NURO traded down $0.08 during mid-day trading on Friday, reaching $4.43. The company had a trading volume of 2,608 shares, compared to its average volume of 17,481. The stock has a fifty day moving average of $4.35 and a two-hundred day moving average of $4.14. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The company has a market capitalization of $9.09 million, a price-to-earnings ratio of -0.97 and a beta of 2.15.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. Hedge funds and other institutional investors own 19.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on NeuroMetrix in a research report on Friday. They set a “sell” rating on the stock.

Read Our Latest Stock Analysis on NURO

About NeuroMetrix

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.